Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEX CORP /DE/IEX · Entity 3323 | Director | May 06, 2026 | May 08, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 04, 2026 | May 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEX CORP /DE/
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 10,025 |
Reported balance
After 2026-05-06 transaction · row 1
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 805 · Balance 10,025 F1: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs vest in full on the earlier of May 6, 2027, and the date of the Issuer's next annual stockholders meeting if it is at least 50 weeks after the prior year's meeting, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs vest in full on the earlier of May 6, 2027, and the date of the Issuer's next annual stockholders meeting if it is at least 50 weeks after the prior year's meeting, subject to the Reporting Person's continuous service through such date.
WEST PHARMACEUTICAL SERVICES INC
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,308.5494 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 791 · Balance 44,308.5494 F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2026 Filed May 8, 2026 20:35 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 805 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002189 · form4.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,025 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. These RSUs vest in full on the earlier of May 6, 2027, and the date of the Issuer's next annual stockholders meeting if it is at least 50 weeks after the prior year's meeting, subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:18 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000057 · form4.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,308.5494 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. Read SEC document |
| May 08, 2025 Filed May 12, 2025 21:53 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 895 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001582 · form4.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,220 Read SEC document |
| May 06, 2025 Filed May 8, 2025 20:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013688 · form4.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,860.9294 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. Read SEC document |
| May 07, 2024 Filed May 8, 2024 19:59 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0000832101-24-000020 · primary_doc.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,325 Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:26 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 564 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013396 · form4.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,786.29 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. Read SEC document |
| May 25, 2023 Filed May 30, 2023 19:26 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 770 | $0.00 | $0.00 |
DisclosureSEC source: 0001842832-23-000002 · primary_doc.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,580 Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:39 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-23-003704 · primarydocument.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,222.29 F1 · price: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:48 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004428 · primarydocument.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,606.29 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| May 06, 2022 Filed May 10, 2022 17:09 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 825 | $0.00 | $0.00 |
DisclosureSEC source: 0000832101-22-000020 · primary_doc.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,810 Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 14:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 48 | $469.01 | $22,512.48 |
DisclosureSEC source: 0001562180-22-000059 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,879.2996 Underlying: Common Stock · 48 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 17:48 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 53 | $424.54 | $22,500.62 |
DisclosureSEC source: 0001562180-21-006184 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,831.2996 Underlying: Common Stock · 53 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 18:58 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 63 | $359.10 | $22,623.30 |
DisclosureSEC source: 0001562180-21-004614 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,778.2996 Underlying: Common Stock · 63 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| May 12, 2021 Filed May 14, 2021 20:13 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 665 | $0.00 | $0.00 |
DisclosureSEC source: 0001226577-21-000002 · primary_doc.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,985 Read SEC document |
| May 04, 2021 Filed May 6, 2021 23:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-003308 · primarydocument.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,974.29 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| March 31, 2021 Filed Apr 13, 2021 18:40 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 80 | $281.78 | $22,542.40 |
DisclosureSEC source: 0001562180-21-002797 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,715.2996 Underlying: Common Stock · 132 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:18 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 950 | $0.00 | $0.00 |
DisclosureSEC source: 0001574068-20-000003 · primary_doc.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,320 Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-003467 · primarydocument.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,227.7782 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 31, 2019 Filed Jan 9, 2020 20:35 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 150 | $150.33 | $22,549.50 |
DisclosureSEC source: 0001562180-20-000300 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,635.2996 Underlying: Common Stock · 150 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:13 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 159 | $141.82 | $22,549.38 |
DisclosureSEC source: 0001562180-19-005054 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,485.2996 Underlying: Common Stock · 159 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 16:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 180 | $125.15 | $22,527.00 |
DisclosureSEC source: 0001562180-19-003737 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,326.2996 Underlying: Common Stock · 180 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 10, 2019 Filed May 14, 2019 20:32 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 845 | $0.00 | $0.00 |
DisclosureSEC source: 0001226577-19-000002 · primary_doc.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Read SEC document |
| May 07, 2019 Filed May 9, 2019 19:10 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-002729 · primarydocument.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,276.8922 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 18:15 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 204 | $110.20 | $22,480.80 |
DisclosureSEC source: 0001562180-19-002088 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,146.2996 Underlying: Common Stock · 204 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:12 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 255 | $98.03 | $24,997.65 |
DisclosureSEC source: 0001562180-19-000126 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,942.2996 Underlying: Common Stock · 255 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| September 28, 2018 Filed Oct 2, 2018 17:01 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 203 | $123.74 | $25,119.22 |
DisclosureSEC source: 0001562180-18-004085 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,687.2996 Underlying: Common Stock · 203 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| June 29, 2018 Filed Aug 1, 2018 20:34 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 266.8836 | $99.29 | $26,498.87 |
DisclosureSEC source: 0001562180-18-003445 · primarydocument.xml · derivative · entry 4 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,484.2996 Underlying: Common Stock · 266.8836 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · balance_after: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| May 01, 2018 Filed May 3, 2018 21:50 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002201 · primarydocument.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,607.3235 F1 · price: These shares of restricted stock units will vest in full after 12 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| April 25, 2018 Filed Apr 26, 2018 21:07 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 945 | $0.00 | $0.00 |
DisclosureSEC source: 0001226577-18-000001 · primary_doc.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,525 Read SEC document |
| March 29, 2018 Filed Aug 1, 2018 20:34 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 295.457 | $86.72 | $25,622.03 |
DisclosureSEC source: 0001562180-18-003445 · primarydocument.xml · derivative · entry 3 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,217.416 Underlying: Common Stock · 295.457 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · balance_after: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| December 29, 2017 Filed Aug 1, 2018 20:34 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 264.0821 | $99.16 | $26,186.38 |
DisclosureSEC source: 0001562180-18-003445 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,921.959 Underlying: Common Stock · 264.0821 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · balance_after: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 19:52 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 259.5246 | $96.33 | $25,000.00 |
DisclosureSEC source: 0001562180-17-003158 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,657.8769 Underlying: Common Stock · 259.5246 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 16:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 264.8586 | $94.39 | $25,000.00 |
DisclosureSEC source: 0001562180-17-002371 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,385.8375 Underlying: Common Stock · 264.8586 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 02, 2017 Filed May 3, 2017 18:47 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001678 · primarydocument.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,717.439 F1 · price: These shares of restricted stock units will vest in full after 12 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 19:15 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 306.035 | $81.69 | $25,000.00 |
DisclosureSEC source: 0001562180-17-001421 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109.7668 Underlying: Common Stock · 306.035 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 23:59 UTC | IDEX CORP /DE/ IEX · Entity 3323 | GrantCOMMON STOCK | 1,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001322851-17-000005 · primary_doc.xml · nonDerivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,580 Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 19:55 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 293.4272 | $85.20 | $25,000.00 |
DisclosureSEC source: 0001562180-17-000143 · primarydocument.xml · derivative · entry 2 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,791.76 Underlying: Common Stock · 293.4272 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 19:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 337.2909 | $74.12 | $25,000.00 |
DisclosureSEC source: 0001225208-16-039973 · doc4.xml · derivative · entry 1 BUTHMAN MARK A · CIK 0001223783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,474.7182 Underlying: Common Stock · 337.2909 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.